Antisoma Starts Phase II Leukemia Trial
Posted on: Monday, 6 August 2007, 12:09 CDT
Antisoma has started a randomized Phase II trial of its investigational cancer drug in acute myeloid leukemia.
The UK biotech said that it will recruit around 70 patients at major cancer centers in the US. The trial tests Antisoma's anticancer aptamer AS1411 in patients with relapsed or refractory acute myeloid leukemia (AML). It evaluates addition of AS1411 to the current standard therapy, cytarabine (Ara-C).
Patients are being randomly assigned to one of three groups: cytarabine alone, cytarabine plus 10 mg/kg/day AS1411 or cytarabine plus 40 mg/kg/day AS1411. Efficacy and safety will be compared to see whether patients receiving a cytarabine-AS1411 combination do better than those receiving cytarabine alone and whether the two doses of AS1411 have different effects. Initial results are expected in 2008.
Preclinical data suggest that AS1411 has potential against various blood cancers and solid tumors, according to Antisoma. AML was selected as the lead blood-cancer indication because cancer cells from AML patients and AML cell lines show particularly high sensitivity to AS1411. There is also evidence for a synergistic effect when AS1411 is combined with cytarabine.
Phase I testing of AS1411 was conducted in solid tumors. This showed a favorable safety profile and evidence of anticancer activity in renal cancer. A Phase II trial in renal cancer is expected to start shortly.
Antisoma's CEO, Glyn Edwards, said: "We intend to explore the potential of AS1411 in a number of cancers where new treatment options are needed. Our robust, randomized trials should provide clear evidence of any benefit associated with AS1411 and therefore have the potential to add significantly to its value over the next couple of years."
Source: Datamonitor
Related Articles
- First-of-its-Kind Collaboration Among Advocacy Groups Provides Lung Cancer Patients Personalized Information About Clinical Trials
- Enrollment of Breast and Ovarian Cancer Patients Commenced for Combination Therapy Trial to Include Generex Biotechnology's Novel Immunotherapeutic Vaccine
- Antisoma Announces Start of Phase III Lung Cancer Trial of ASA404
- ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
- First Prostate Cancer Patients Treated in a Phase I Clinical Trial As Part of a Collaboration Between Generex Biotechnology and the Saint Savas Cancer Hospital
- Array BioPharma Advances ErbB-2 Inhibitor, ARRY-380, into Phase 1 Cancer Patient Trial
- Affymax Presents Results From Ongoing Phase 2 Clinical Trial of Hematide(TM) in Anemic Cancer Patients Receiving Chemotherapy
- Red Tape Denies Cancer Patients 23 Vital Drugs
- A.P. Pharma Initiates APF530 Phase 2 Clinical Trial Program in Cancer Patients
- FDA Approves Kepivance for Severe Oral Mucositis in Cancer Patients Undergoing Bone Marrow Transplant; Pivotal Phase 3 Study Published in This Week's New England Journal of Medicine
 |
 |
User Comments (0)
RSS Feeds